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Abstract 
Objectives: We aimed to conduct a large audit of routine care for patients with 
ANCA-associated vasculitis (AAV). 
Methods: We invited all 34 hospitals within one health region in England to 
undertake a retrospective case note audit of all patients newly-diagnosed or 
treated with Cyclophosphamide or Rituximab for AAV April 2013-December 
2014. We compared clinical practice to the BSR guideline for the management of 
adults with AAV, and use of Rituximab to the NHS England commissioning policy 
and NICE Technology Appraisal. 
Results: We received data from 213 patients. Among 130 newly diagnosed 
patients, delay from admission to diagnosis ranged from 0-53 days (median 6, 
IQR 3-10.5) for those diagnosed as in-patients. BVAS score was recorded in 8% 
at diagnosis. Remission at 6 months was achieved in 83% of patients. 1-year 
survival was 91.5%. 130 patients received Cyclophosphamide for new-diagnosis 
or relapse. The correct dose of i.v. cyclophosphamide (within 100mg of the 
target dose calculated for age, weight and creatinine) was administered in 58%. 
25% of patients had an infection requiring hospital admission during or within 6 
months of completing their cyclophosphamide therapy. 76 patients received 
Rituximab for new-diagnosis or relapse. 97% patients met NHS England or NICE 
eligibility criteria. PJP prophylaxis (recommended in the summary of product 
characteristics) was given in only 65% of patients.  
Conclusion: We identified opportunities to improve care, including compliance 
with safety standards for delivery of cyclophosphamide. Development of a 
national treatment protocol / checklist to reduce this heterogeneity in care 
should be considered as a priority. 
Key words: ANCA-associated vasculitis, Audit, Routine care, Cyclophosphamide, 
Survival 
Key messages: 
1. Infections requiring hospital admission occurred in 25% of ANCA-
associated vasculitis patients receiving cyclophosphamide. 
2. Only 58% of ANCA-associated vasculitis patients on i.v. cyclophosphamide 
received the correct dose (within a 10% tolerance). 
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3. Tertiary-referral centres treated ANCA-associated vasculitis sooner, and 
more patients received correct doses of cyclophosphamide 
 
Introduction 
ANCA-associated vasculitis (AAV) has high mortality, with the greatest mortality 
risk occurring within the first year after diagnosis. Yet there is very little data on 
the process and outcomes of routine NHS clinical care during this time period, 
aside from individual centre case series or small clinical trials. However, the 
patient charity Vasculitis UK frequently describes that their members report 
variations in clinical practice and outcomes throughout the UK.  
Remission induction of AAV with cyclophosphamide is probably the most 
frequent non-cancer indication for cytotoxic chemotherapy. National guidance 
from the National Chemotherapy Advisory Group, designed to ensure quality and 
safety of all chemotherapy services, is also applicable to non-cancer 
chemotherapy [1]. The publication of BSR guidelines on the Management of 
adults with ANCA-associated vasculitis[2], and an NHS England commissioning 
policy for the use of Rituximab in AAV [3], followed by a NICE Technology 
Appraisal [4] provided further benchmarks against which to assess care.  
The aim of this audit was to compare current practices, compliance with national 
guidelines and outcomes within a large, representative and geographically-
defined area in England. 
Methods 
Rheumatology units in all 34 hospitals within one of the four health regions in 
England (Midlands and East - population 6,980,000) were invited to undertake a 
retrospective case note audit of all ANCA-associated vasculitis patients who were 
either newly diagnosed, or treated with Cyclophosphamide or Rituximab for 
relapse, during April 2013-December 2014. Each invitation recommended 
involving their hospital’s nephrology unit. Patients were considered to have ANCA-
associated vasculitis if this was their diagnosis given by a hospital physician. We 
developed and piloted a set of audit questions derived from the BSR guidelines, 
NHS England and NICE technology appraisal. We provided guidance on how to 
identify cases through departmental database, clinic letter, day-case and inpatient 
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admissions searches. Data were collected locally, and uploaded onto a web-based 
survey. Survey software was compliant with ISO 27001, the internationally 
recognised gold standard for information security systems, hosted by The Dudley 
Group NHS Foundation Trust clinical audit department. The form ensured complete 
data entry for most questions, as it could not submitted unless questions were 
answered. Data were collected on specialty of attending physician, place of 
diagnosis, dates of symptom onset, admission or first clinic appointment, and 
diagnosis, BVAS organ systems involved, details of remission induction, 
documentation of disease activity and damage, compliance with 
cyclophosphamide and rituximab safety standards, and outcomes including 
hospitalization for infection and death. Diagnostic delay was retrospectively 
estimated from information recorded in the medical notes, and was defined as the 
time from the date of the first reported symptom attributed to AAV to the date of 
diagnosis. Patient age, sex, subtype of AAV diagnosis, and ANCA-type were 
collected later, after completion of initial data entry. Tertiary-referral centres were 
defined as hospitals that at least 2 other hospitals reported that they made tertiary 
referrals to for ANCA-associated vasculitis. Tertiary-referral centres were 
compared to the other non-tertiary centres using chi-squared tests for categorical 
data, and Wilcoxon’s rank sum test for continuous non-normally distributed data. 
1 year survival was calculated using Kaplan-Meier methods. The odds ratio (OR) 
for infection was estimated using logistic regression, and the hazard ratio (HR) for 
death was estimated using cox regression; both were adjusted for confounders 
(age and renal involvement). Available case analysis was used where there were 
missing data. Statistical analyses were performed using Stata 14 statistical 
software (Statacorp, Texas, USA). This project was approved by the audit 
department of each trust that participated. 
Results 
We received data about 213 patients from 20 units: 130 newly diagnosed 
patients, and an additional 83 relapsing patients who were treated with 
cyclophosphamide or rituximab during the audit period. Between 1 and 41 
patients were included by each unit. 144 (68%) were treated primarily by 
Rheumatology, and 69 (32%) by Nephrology. 
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Missing data: There were no missing data for audit outcomes. For the data 
collected at a later stage, there were some missing data (age (1%), sex (7%), 
diagnosis (10%) and ANCA-type (6%)). 
New diagnosis 
Baseline characteristics of the 130 newly diagnosed patients are shown in table 
1. The median age was 67 (interquartile range 56-73), and 52 (43%) were 
female. 57 (49%) had granulomatosis with polyangiitis (GPA), 49 (42%) had 
microscopic polyangiitis (MPA) and 10 (9%) had eosinophilic granulomatosis with 
polyangiitis (EGPA). 72 (55%) were diagnosed as inpatients, and 58 (45%) as 
outpatients. Frequency of organ involvement at diagnosis is shown in table 2. 
Diagnostic delay from first symptoms to diagnosis was median 2.6 (interquartile 
range 1.2-6.1) months. It was shorter in those diagnosed as inpatients (1.8, 
95% CI 0.9-3.7) compared to outpatients (4.1, 95% CI 2.0-12.6). Among 
inpatients, delay from admission to diagnosis ranged from 0-53 days (median 6, 
IQR 3-10.5). BVAS score was recorded in 10/130 (8%) at diagnosis and 8/121 
(7%) at 6 months. The first choice of agent for remission induction was  
Cyclophosphamide (CYC) in 99 (76%), Rituximab in 6 (5%), and other agents in 
25 (19%). Prednisolone dose at treatment initiation was median 55mg, (IQR 40-
60mg, range 0-100mg) and additional i.v. methylprednisolone was administered 
in 60 (46%). At 6 months the prednisolone dose was median 9.5mg (IQR 5-
10mg, range 0-60mg) among the patients documented to be in remission. 
Remission at 6 months was achieved in 101 (83%) of patients. 1-year survival 
was 90.8%. In the 76 patients who were recorded as having renal involvement, 
1-year survival was 85.5%. 
Of the 99 newly diagnosed patients treated with CYC, 74 (75%) received i.v. and 
25 (25%) oral. 24 (24%) had infections requiring hospitalisation during or within 
6 months of CYC treatment. One-year survival in this subgroup was 87.9%. 
Compared to i.v., the crude OR for infection with oral CYC was 2.2 (0.8-6.0) and 
HR for death was 2.3 (0.8-6.6). Once adjusted for age and renal involvement, 
OR for infection remained elevated at 1.8 (0.6-5.1) and HR for death was 1.7 
(0.5-5.3) (table 2) 
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Cyclophosphamide safety standards[1,2] 
130 patients received Cyclophosphamide for new-diagnosis or relapse: 101 
(78%) received i.v. and 29 (22%) received oral (table 3). The correct dose of 
i.v. cyclophosphamide could be calculated for 95 (94%) of these based on BSR 
recommendations for age, weight and renal function, within a tolerance of +/-
100mg, based on the dose-banding for cancer chemotherapy  introduced by NHS 
England which  uses dose-bands within 5-10% of target dose[5]. The correct 
dose was administered in only 50 (58%), with under-dosing in 32 (34%) and 
over-dosing in 13 (8%). 1000mg was the most common dose given to those 
who received an un-recommended dose, and those who were under-dosed were 
on average younger and heavier, and those who were over-dosed were on 
average older and lighter than the whole cohort. At least one FBC was checked 
7-10 days after the first dose of p.o. or i.v. cyclophosphamide in 119 (92%) 
patients. The total cumulative cyclophosphamide dose per patient was median 
6g, interquartile range 4-9g, range 0.1-21g. No patients exceeded a lifetime 
exposure of 25g. Mesna was given in 99 (76%) of patients. PJP prophylaxis was 
given in 106 (82%) of patients. 33 (25%) patients had an infection requiring 
hospital admission during or within 6 months of completing their 
cyclophosphamide therapy. 
Rituximab safety standards, and compliance with NICE / NHS E criteria for eligibility[3,4] 
76 patients received Rituximab for new-diagnosis or relapse (table 4). The 
dosing schedule among the 16 patients newly diagnosed was 1g x2 in 15 (94%), 
and 375mg/m2 x4 in 1 (6%). The dosing schedule among the 60 patients 
treated for relapse was 1g x2 in 35 (58%), 375mg/m2 x4 in 16 (27%), and 1g 
x1 in 7 (12%). 74 (97%) patients met NHS England or NICE eligibility criteria. 
Pneumocystis jiroveci pneumonia (PJP) prophylaxis (recommended in the 
summary of product characteristics (SPC)) was given in only 49 (65%) of 
patients. Immunoglobulins were checked prior to Rituximab in 63/68 (93%) 
patients. 
Tertiary and non-tertiary referral centres 
Of the 130 newly diagnosed patients, 45 (35%) were treated in four tertiary-
referral centres, and 85 (65%) were treated in 16 non-tertiary centres (table 5). 
Delay between admission and diagnosis was median 4, IQR 2-13 days in 
tertiary-referral centres, compared to median 7, IQR 4-11 in non-tertiary centres 
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(p=0.4). Delay between diagnosis and starting immunosuppression was median 
4, IQR 3-10 days in tertiary-referral centres, and median 9, IQR 3-19 in non-
tertiary centres (p=0.01). Of the 130 patients treated with cyclophosphamide, 
42 (32%) were treated in tertiary-referral centres, and 88 (68%) were treated in 
non-tertiary centres. The correct dose of i.v. cyclophosphamide was given in 
23/32 (72%) of patients treated in tertiary-referral centres, compared to 29/57 
(51%) of patients treated in non-tertiary centres (p=0.05). Infections requiring 
hospital admission occurred in 9 (21%) of patients treated in tertiary-referral 
centres, compared to 24 (27%) of patients treated in non-tertiary centres 
(p=0.5). Patients who received Rituximab were more commonly treated in 
tertiary-referral centres (48 (63%)) compared to 28 (37%) treated in non-
tertiary centres. PJP prophylaxis was prescribed to 73% of patients on Rituximab 
treated in tertiary-referral centres compared to 52% treated at non-tertiary 
centres (p=0.07). 
Discussion 
Main findings 
We identified a cohort of 213 patients receiving routine clinical care for AAV in a 
large health region of England. We found long delaysbetween admission and 
diagnosis in some in-patients diagnosed with AAV (max >7 weeks). We found 
that a guideline recommended dose of i.v. cyclophosphamide, based on age, 
weight and renal function, was prescribed in <60% of patients, and that 
adherence to other safety standards for monitoring and prophylactic medication 
had room for improvement. Rituximab treatment was prescribed to eligible 
patients in compliance with the NICE technology appraisal and NHS England 
commissioning policy, but there was opportunity to improve the numbers of 
patients co-prescribed PJP prophylaxis as is recommended in the SPC. We found 
that delay between diagnosis and starting immunosuppressive treatment and 
prescription of the correct dose of cyclophosphamide were significantly better in 
tertiary-referral centres which provided care for much larger numbers of patients 
than non-tertiary centres. 
We found that 25% of patients on cyclophosphamide were admitted with 
infection during or in the 6 months after cyclophosphamide treatment, which is 
higher than expected based on previous studies[6–8]. Our best estimates of the 
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effect of giving cyclophosphamide by the p.o. compared to the i.v. route, once 
adjusted for the effects of age and renal involvement, were that it increased 
infections by 80% and risk of death by 70% – but our confidence intervals were 
wide as our sample size is small and these were not statistically significant.  
Strengths and limitations 
This is the largest collaborative audit of a rare autoimmune rheumatic disease, 
and the first time services for people with AAV have been able to benchmark 
their care not just against standards, but also against other providers. Its main 
strength is in the large and unselected group of patients who were diagnosed 
with AAV by their rheumatologist or renal physician, across a range of different 
sized healthcare providers ranging from smaller district general hospitals to large 
tertiary-referral centres. It therefore enables a representative overview of the 
process and outcome of care in England, which cannot be adequately gained 
from existing clinical trial reports or cohorts from single centres.  
As it is an audit there are limitations, particularly incomplete case capture. Cases 
were contributed by 20 (59%) of 34 invited units. A cohort of 130 newly 
diagnosed adult patients were identified over 21 months in an adult catchment 
population of 6,980,000, which equates to an incidence rate of 10.6 per million 
person years, suggesting we identified ~50% of all expected incident cases [9] 
which compares favourably with the first year of the national Rheumatoid and 
Inflammatory Arthritis audit which captured about 42% of expected cases[10]. 
The demographics of cases included in the audit were very similar to a recent 
epidemiological study [11], and were received from the expected mix of district 
general and tertiary-referral hospitals. Data were collected and entered by a 
large team of people, which may lead to variation in interpretation of the 
questions, however a set of explanatory notes covering each question minimised 
this risk (online supplement). There are some missing data, particularly for 
baseline demographics as these were collected later, however the main 
outcomes have no missing data due to the electronic form not allowing 
submission until all questions were answered. 
The audit captured data from patients treated between April 2013 and December 
2014, whilst the BSR, NHS England and NICE standards were introduced during 
this period, although CYC dosing guidance is identical to the 2007 guideline. This 
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might explain the low use of BVAS to document outcomes (which these 
documents recommend/require). BVAS training can be completed online[12], 
and BVAS takes less than 3 minutes to complete[13]. It is possible that care has 
improved post-audit as a response to these guidelines.  
Real life audit comparisons to clinical trials. 
Our audit is the first description of routine care of patients with AAV across a 
large health region, and compliance with safety standards. The baseline 
characteristics of included patients are similar to other UK epidemiological 
studies from the Midlands and Norfolk [11,14]. Our cohort also had similar 
remission[6] (83%) and survival rates (1 year survival 90.8%) to other studies 
[8,15–17]. 
Of note, our audit of routine practice found higher rates of serious infection than 
in the EUVAS clinical trials[18]. This is likely to be influenced by selected 
populations, and possibly by protocolised treatment in clinical trials. For 
example, the CYCLOPS trial reported 11% of patients had severe infections 
requiring hospital treatment during median 18 months follow-up, so the follow 
up time was longer than in our audit, and the trial excluded those with creatinine 
>500 µmol/L, and age<18 or >80 which are risk factors for serious infection[6]. 
Based on these exclusion criteria alone, 7% of the patients included in our audit 
would have been excluded from CYCLOPS. Our results are similar to a recent 
study of all patients presenting to a single centre, where 22% of patients 
receiving cyclophosphamide for AAV were admitted with infection during the first 
year after commencing treatment[19]. This suggests 22-25% may be a realistic 
estimate of the risk of hospitalisation with infection in the year after starting 
cyclophosphamide that patients should receive counselling about pre-treatment. 
We did not find a statistically significant increased risk of infection and death in 
patients treated with p.o. compared to i.v. cyclophosphamide, however, our 
audit was under-powered for this analysis. A previous meta-analysis of 3 
randomised controlled trials comparing p.o. vs i.v. cyclophosphamide found i.v. 
cyclophosphamide conferred a significantly lower risk of infection (OR 0.45, 95% 
CI 0.23-0.89) [20]  
Our findings reflect some of the findings common to rare diseases, which are 
highlighted in the UK Strategy for Rare Diseases[21]. For example, people with 
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rare diseases are often slow to benefit from advances in treatment[21], and it is 
notable that although the minority of patients (41%) overall were treated at 
tertiary-referral centres, the majority of patients receiving Rituximab (63%) 
were treated in tertiary referral centres. Although, tertiary referral centres are 
more likely to treat severe disease, they may also be quicker to embrace new 
treatments, facilitated by these centres fulfilling the ‘specialised centre’ 
requirements of the NHS England policy for access to this drug. 
Clinical implications and Conclusion 
We identified opportunities to improve our care, including improving compliance 
with safety standards for the delivery of cyclophosphamide for the 42% of 
patients who received an incorrect dose of i.v. cyclophosphamide. Our 
comparison of p.o. versus i.v. cyclophosphamide adds to the level of certainty 
from other studies that p.o. cyclophosphamide has higher toxicity. Development 
of a national treatment protocol / checklist to reduce heterogeneity in care 
should be considered as a priority. More than half of patients were diagnosed as 
inpatients, and we found a long delay between admission and diagnosis in some 
patients (up to 53 days). Increased awareness among acute admitting 
physicians, and earlier ANCA-testing could reduce diagnostic delay and perhaps 
reduce organ damage among newly diagnosed patients. Our finding that 25% of 
patients on cyclophosphamide were admitted with infection during or following 
cyclophosphamide therapy is higher than in clinical trials, and requires increased 
vigilance for infection, and changes to the expectations we give patients when 
counselling them before starting treatment. 
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Table 1: Newly diagnosed patients (n=130) 
Characteristic  
Age, median (IQR), years 67 (56-73) 
Female 52 (43) 
Male 68 (57) 
GPA 57 (49) 
MPA 49 (42) 
EGPA 10 (9) 
PR3-ANCA 52 (43) 
MPO-ANCA 55 (45) 
ANCA negative 9 (8) 
p-ANCA only (not PR3/MPO) 3 (3) 
c-ANCA only (not PR3/MPO) 1 (1) 
BVAS organ system Involved at diagnosis 
Constitutional symptoms 88 (73) 
Renal 76 (63) 
Chest 62 (50) 
ENT 55 (47) 
Cutaneous 30 (25) 
Nervous system 28 (23) 
Mucous membranes / Eyes 20 (17) 
Abdominal 13 (11) 
Cardiovascular 8 (7) 
Audit outcomes  
Delay from 1st symptom to diagnosis, median (IQR), months 2.6 (1.2-6.1) 
BVAS score recorded  
At diagnosis 10 (8) 
At 6 months 8 (7) 
First choice of remission induction treatment  
Cyclophosphamide 99 (76) 
Rituximab 6 (5) 
Other agent 25 (19) 
Glucocorticoids  
Prednisolone at diagnosis, median (IQR), mg 55 (40-60) 
Additional i.v. methylprednisolone  60 (46%) 
Prednisolone at 6 months, median (IQR),mg 10 ( 5-10) 
Remission at 6 months 101 (83) 
Survival at 1 year  
All patients (n=130) 90.8% (95% CI 84.3-94.7)  
Patients with documented renal involvement (n=76) 85.5% (95% CI 75.4-91.7). 
Values are n (%) unless otherwise stated. 
GPA granulomatosis with polyangiitis, MPA microscopic polyangiitis, EGPA eosinophilic 
granulomatosis with polyangiitis 
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Table 2: Risk of infection and death in newly diagnosed patients treated with p.o. compared to i.v. 
cyclophosphamide 
 Infection Mortality 
CYC route N (%) Crude OR for 
infection 
Adjusted 
ORa 
N (%) Crude HR for 
death 
Adjusted 
HRa 
i.v. 15/74 (20.2) 1 1 9/74 (12.2) 1 1 
p.o. 9/25 (36.0) 2.2 (0.8-6.0) 1.8 (0.6-5.1) 6/25 (24.0) 2.3 (0.8-6.5) 1.7 (0.5-5.3) 
aAdjusted for age and renal involvement. CYC cyclophosphamide, OR odds ratio from logistic 
regression, HR hazard ratio from Cox regression. 
 
 
Table 3: Patients treated with Cyclophosphamide for new diagnosis or relapse (n=130) 
Characteristic  
Age, median (IQR), years 65 (56-72) 
Female 50 (42) 
Male 68 (58) 
GPA 64 (58) 
MPA 39 (35) 
EGPA 8 (7) 
PR3-ANCA 58 (49) 
MPO-ANCA 46 (39) 
ANCA negative 8 (7) 
p-ANCA only (not PR3/MPO) 4 (3) 
c-ANCA only (not PR3/MPO) 2 (2) 
Treatment  
p.o. cyclophosphamide 29 (22) 
i.v. cyclophosphamide 101 (78) 
Audit outcome  
Correct dose of i.v. cyclophosphamide, within 
100mg 
50 (58) 
Underdosed, >100mg 32 (34) 
Overdosed, >100mg 13 (8) 
FBC was checked 7-10 days after the first dose 119 (92) 
Total cumulative dose of cyclophosphamide, median 
(IQR), g 
range 
 
6 (4-9) 
0.1-21g 
Co-prescription of Mesna 99 (76) 
Co-prescription of PJP prophylaxis 106 (82) 
Admission with infection during or within 6 months of 
cyclophosphamide therapy 
33 (25) 
All values are n (%) unless otherwise stated. 
GPA granulomatosis with polyangiitis, MPA microscopic polyangiitis, EGPA eosinophilic 
granulomatosis with polyangiitis, FBC full blood count, PJP pneumocystis jiroveci pneumonia 
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Table 4: Patients treated with Rituximab for new diagnosis or relapse (n=76) 
Characteristic  
Age, median (IQR), years 50 (36-63) 
Female 34 (47) 
Male 39 (53) 
GPA 60 (82) 
MPA 11 (15) 
EGPA 2 (3) 
PR3-ANCA 60 (82) 
MPO-ANCA 11 (15) 
ANCA negative 1 (1) 
p-ANCA only (not PR3/MPO) 1 (1) 
c-ANCA only (not PR3/MPO) 0 
Treatment  
Rituximab given for New diagnosisa 16 (21) 
Regimen 
1 g x2 
375mg/m2 x4 
 
15 (94) 
1 (6) 
Diagnosis, % 
GPA 
MPA 
EGPA 
 
67 
33 
0 
Rituximab given for relapse 60 (79)  
Regimen 
1g x2 
375mg/m2 x4 
1g x1 
 
35 (58) 
16 (27) 
7 (12) 
Diagnosis 
GPA 
MPA 
EGPA 
 
95 
2 
2 
Audit outcomes  
Treated at referral centres 48 (63) 
Treated at other centres 28 (37) 
Immunoglobulins checked prior to treatment 63/68 (93) 
Co-prescription of PJP prophylaxis 49 (65) 
Met NICE TA / NHS England eligibility criteria 74 (96) 
All values are n (%) unless otherwise stated. aFirst choice treatment (n=6), after switching (n=10). 
GPA granulomatosis with polyangiitis, MPA microscopic polyangiitis, EGPA eosinophilic 
granulomatosis with polyangiitis, PJP pneumocystis jiroveci pneumonia, NICE National Institute for 
Health and Care Excellence, TA technology appraisal, NHS National Health Service 
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Table 5: Comparison of Referral and non-referral centres 
 Referral Centres Non-referral Centres p-value 
Newly diagnosed patients, n (%) 45 (35) 84 (65)  
Delay between admission & diagnosis, 
median (IQR) 
4 (2-13) 7 (4-11) 0.4 
Delay between diagnosis and starting 
immunosuppression, median (IQR) 
4 (3-10) 9 (3-19) 0.01 
Patients treated with 
Cyclophosphamide, n (%) 
42 (32) 88 (68)  
Correct dose of i.v. cyclophosphamide 23/32 (72) 29/57 (51) 0.05 
Admission with infection during or 
within 6 months of cyclophosphamide 
therapy, n (%) 
9 (21) 24 (27) 0.5 
Patients treated with Rituximab, n (%) 48 (63) 28 (37)  
Co-prescription of PJP prophylaxis, % 73 52 0.07 
PJP pneumocystis jiroveci pneumonia 
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